Antonarakis ES, Park SH, Goh JC, Shin SJ, et al. Pembrolizumab Plus Olaparib for Patients With Previously Treated and Biomarker-Unselected Metastatic Castration-Resistant Prostate Cancer: The Randomized, Open-Label, Phase III KEYLYNK-010 Trial. J Clin Oncol 2023 Jun 8:JCO2300233. doi: 10.1200/JCO.23.00233.
PMID: 37290035